Hydrastine

Hydrastine ((-) -β-Hydrastine; (1R,9S) -β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells) . Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM) . Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage[1][2].

Product Specifications

CAS Number

[118-08-1]

Product Name Alternative

(-) -β-Hydrastine; (1R,9S) -β-Hydrastine

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Dopamine Receptor; OAT; Tyrosine Hydroxylase

Type

Natural Products

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Hydrastine.html

Concentration

10mM

Purity

99.57

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1O[C@H]([C@@H]2N(C)CCC3=C2C=C(OCO4)C4=C3)C5=C1C(OC)=C(OC)C=C5

Molecular Formula

C21H21NO6

Molecular Weight

383.39

Precautions

H302, H312, H332

References & Citations

[1]Yin SY, et al. Effects of (1R,9S) -beta-hydrastine on l-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol. 2004 Mar 19;488 (1-3) :71-7.|[2]Oyanna VO, et al. Goldenseal-Mediated Inhibition of Intestinal Uptake Transporters Decreases Metformin Systemic Exposure in Mice. Drug Metab Dispos. 2023 Nov;51 (11) :1483-1489.